Free Trial
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel
OTCMKTS:BICX

Biocorrx Q1 2025 Earnings Report

Biocorrx logo
$0.34 -0.03 (-8.92%)
As of 03:15 PM Eastern
ProfileEarnings HistoryForecast

Biocorrx EPS Results

Actual EPS
-$0.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biocorrx's next earnings date is estimated for Monday, August 17, 2026, based on past reporting schedules.

Conference Call Resources

Biocorrx Earnings Headlines

Biocorrx (OTCMKTS:BICX) Stock Price Passes Above Fifty Day Moving Average - What's Next?
June 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30834293
BioCorRx Inc.
April 21, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/BICX/financials
SpaceX will crumble without these 5 companies
The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.tc pixel
June 16 at 1:00 AM  |  InvestPub (Ad)
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-issuance-u-123000683.html
BioCorRx, Inc. Announces Initiation of Clinical Study by Majority-Owned Subsidiary BioCorRx Pharmaceuticals, Inc. Evaluating Long-Acting Naltrexone Implant With or Without ...
January 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-initiation-clinical-133000445.html
BioCorRx Announces Appointment of Louis Lucido as Board Chair
January 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-announces-appointment-louis-lucido-133000529.html
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View Biocorrx Profile
Earnings Tools